523 related articles for article (PubMed ID: 28423034)
21. Cutaneous squamous cell carcinoma with perineural invasion: a case report and review of the literature.
Adams CC; Thomas B; Bingham JL
Cutis; 2014 Mar; 93(3):141-4. PubMed ID: 24738095
[TBL] [Abstract][Full Text] [Related]
22. PD-1 and Tim-3 Pathways Regulate CD8+ T Cells Function in Atherosclerosis.
Qiu MK; Wang SC; Dai YX; Wang SQ; Ou JM; Quan ZW
PLoS One; 2015; 10(6):e0128523. PubMed ID: 26035207
[TBL] [Abstract][Full Text] [Related]
23. Characterization of age-associated exhausted CD8⁺ T cells defined by increased expression of Tim-3 and PD-1.
Lee KA; Shin KS; Kim GY; Song YC; Bae EA; Kim IK; Koh CH; Kang CY
Aging Cell; 2016 Apr; 15(2):291-300. PubMed ID: 26750587
[TBL] [Abstract][Full Text] [Related]
24. Galectin-1 is associated with poor prognosis in patients with cutaneous head and neck cancer with perineural spread.
Chawla S; Warren TA; Wockner LF; Lambie DL; Brown IS; Martin TP; Khanna R; Leggatt GR; Panizza BJ
Cancer Immunol Immunother; 2016 Feb; 65(2):213-22. PubMed ID: 26759008
[TBL] [Abstract][Full Text] [Related]
25. Distinct patterns of infiltrating CD8+ T cells in HPV+ and CD68 macrophages in HPV- oropharyngeal squamous cell carcinomas are associated with better clinical outcome but PD-L1 expression is not prognostic.
Oguejiofor K; Galletta-Williams H; Dovedi SJ; Roberts DL; Stern PL; West CM
Oncotarget; 2017 Feb; 8(9):14416-14427. PubMed ID: 28122336
[TBL] [Abstract][Full Text] [Related]
26. Immune Co-inhibitory Receptors PD-1, CTLA-4, TIM-3, LAG-3, and TIGIT in Medullary Thyroid Cancers: A Large Cohort Study.
Shi X; Li CW; Tan LC; Wen SS; Liao T; Zhang Y; Chen TZ; Ma B; Yu PC; Lu ZW; Qu N; Wang Y; Shi RL; Wang YL; Ji QH; Wei WJ
J Clin Endocrinol Metab; 2021 Jan; 106(1):120-132. PubMed ID: 33000173
[TBL] [Abstract][Full Text] [Related]
27. Immune gene expression in head and neck squamous cell carcinoma patients.
Lecerf C; Kamal M; Vacher S; Chemlali W; Schnitzler A; Morel C; Dubot C; Jeannot E; Meseure D; Klijanienko J; Mariani O; Borcoman E; Calugaru V; Badois N; Chilles A; Lesnik M; Krhili S; Choussy O; Hoffmann C; Piaggio E; Bieche I; Le Tourneau C
Eur J Cancer; 2019 Nov; 121():210-223. PubMed ID: 31593831
[TBL] [Abstract][Full Text] [Related]
28. Tumor-Infiltrating T Cells Concurrently Overexpress CD200R with Immune Checkpoints PD-1, CTLA-4, and TIM-3 in Non-Small-Cell Lung Cancer.
Su Y; Yamazaki S; Morisue R; Suzuki J; Yoshikawa T; Nakatsura T; Tsuboi M; Ochiai A; Ishii G
Pathobiology; 2021; 88(3):218-227. PubMed ID: 33321503
[TBL] [Abstract][Full Text] [Related]
29. PD-L1 Expression is Increased in Metastasizing Squamous Cell Carcinomas and Their Metastases.
García-Díez I; Hernández-Ruiz E; Andrades E; Gimeno J; Ferrándiz-Pulido C; Yébenes M; García-Patos V; Pujol RM; Hernández-Muñoz I; Toll A
Am J Dermatopathol; 2018 Sep; 40(9):647-654. PubMed ID: 29742559
[TBL] [Abstract][Full Text] [Related]
30. Frequency and functional characterization of exhausted CD8
Taghiloo S; Allahmoradi E; Tehrani M; Hossein-Nataj H; Shekarriz R; Janbabaei G; Abediankenari S; Asgarian-Omran H
Eur J Haematol; 2017 Jun; 98(6):622-631. PubMed ID: 28306177
[TBL] [Abstract][Full Text] [Related]
31. TIM-3 plays a more important role than PD-1 in the functional impairments of cytotoxic T cells of malignant Schwannomas.
Li Z; Liu X; Guo R; Wang P
Tumour Biol; 2017 May; 39(5):1010428317698352. PubMed ID: 28475007
[TBL] [Abstract][Full Text] [Related]
32. TIM-3 Dictates Functional Orientation of the Immune Infiltrate in Ovarian Cancer.
Fucikova J; Rakova J; Hensler M; Kasikova L; Belicova L; Hladikova K; Truxova I; Skapa P; Laco J; Pecen L; Praznovec I; Halaska MJ; Brtnicky T; Kodet R; Fialova A; Pineau J; Gey A; Tartour E; Ryska A; Galluzzi L; Spisek R
Clin Cancer Res; 2019 Aug; 25(15):4820-4831. PubMed ID: 31076549
[TBL] [Abstract][Full Text] [Related]
33. The role of PD-L1 in the radiation response and prognosis for esophageal squamous cell carcinoma related to IL-6 and T-cell immunosuppression.
Chen MF; Chen PT; Chen WC; Lu MS; Lin PY; Lee KD
Oncotarget; 2016 Feb; 7(7):7913-24. PubMed ID: 26761210
[TBL] [Abstract][Full Text] [Related]
34. Immune-Related Gene Expression Profiling After PD-1 Blockade in Non-Small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, and Melanoma.
Prat A; Navarro A; Paré L; Reguart N; Galván P; Pascual T; Martínez A; Nuciforo P; Comerma L; Alos L; Pardo N; Cedrés S; Fan C; Parker JS; Gaba L; Victoria I; Viñolas N; Vivancos A; Arance A; Felip E
Cancer Res; 2017 Jul; 77(13):3540-3550. PubMed ID: 28487385
[TBL] [Abstract][Full Text] [Related]
35. Specific blockade CD73 alters the "exhausted" phenotype of T cells in head and neck squamous cell carcinoma.
Deng WW; Li YC; Ma SR; Mao L; Yu GT; Bu LL; Kulkarni AB; Zhang WF; Sun ZJ
Int J Cancer; 2018 Sep; 143(6):1494-1504. PubMed ID: 29663369
[TBL] [Abstract][Full Text] [Related]
36. Disruption of CTLA-4 expression on peripheral blood CD8 + T cell enhances anti-tumor efficacy in bladder cancer.
Zhang W; Shi L; Zhao Z; Du P; Ye X; Li D; Cai Z; Han J; Cai J
Cancer Chemother Pharmacol; 2019 May; 83(5):911-920. PubMed ID: 30848330
[TBL] [Abstract][Full Text] [Related]
37. Differential effects of PD-1 and CTLA-4 blockade on the melanoma-reactive CD8 T cell response.
Gangaev A; Rozeman EA; Rohaan MW; Isaeva OI; Philips D; Patiwael S; van den Berg JH; Ribas A; Schadendorf D; Schilling B; Schumacher TN; Blank CU; Haanen JBAG; Kvistborg P
Proc Natl Acad Sci U S A; 2021 Oct; 118(43):. PubMed ID: 34670835
[TBL] [Abstract][Full Text] [Related]
38. Combination anti-CTLA-4 plus anti-PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies.
Wei SC; Anang NAS; Sharma R; Andrews MC; Reuben A; Levine JH; Cogdill AP; Mancuso JJ; Wargo JA; Pe'er D; Allison JP
Proc Natl Acad Sci U S A; 2019 Nov; 116(45):22699-22709. PubMed ID: 31636208
[TBL] [Abstract][Full Text] [Related]
39. PD-1 blockade induces responses by inhibiting adaptive immune resistance.
Tumeh PC; Harview CL; Yearley JH; Shintaku IP; Taylor EJ; Robert L; Chmielowski B; Spasic M; Henry G; Ciobanu V; West AN; Carmona M; Kivork C; Seja E; Cherry G; Gutierrez AJ; Grogan TR; Mateus C; Tomasic G; Glaspy JA; Emerson RO; Robins H; Pierce RH; Elashoff DA; Robert C; Ribas A
Nature; 2014 Nov; 515(7528):568-71. PubMed ID: 25428505
[TBL] [Abstract][Full Text] [Related]
40. Distinct predictive biomarker candidates for response to anti-CTLA-4 and anti-PD-1 immunotherapy in melanoma patients.
Subrahmanyam PB; Dong Z; Gusenleitner D; Giobbie-Hurder A; Severgnini M; Zhou J; Manos M; Eastman LM; Maecker HT; Hodi FS
J Immunother Cancer; 2018 Mar; 6(1):18. PubMed ID: 29510697
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]